SAT-019 The Associations of Kisspeptin with Reproductive Hormones and Oocyte Maturation in Infertile Patients Who Underwent IVF Treatment
Authors: Qin Lixian , Sitticharoon Chantacha , Petyim Somsin , Keadkraichaiwat Issarawan , Sripong Chanakarn , Sririwichitchai Rungnapa , Maikaew Pailin , Churintaraphan Malika 
Published: May 2020

Abstract
Kisspeptin has been recognized as a stimulatory factor of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin has been successfully used to trigger ovulation in in vitro fertilization (IVF) treatment (1). This study aimed to 1)compare reproductive hormones (FSH, LH, estradiol, progesterone, and AMH), serum and follicular fluid kisspeptin between successful and unsuccessful clinical pregnancy in different stages of IVF treatment; 2) determine the correlations of serum or follicular fluid kisspeptin with reproductive hormones as well as biochemical and clinical outcomes; and 3) compare the levels of kisspeptin between serum and follicular fluid. In this study, 30 infertile female patients (age 26–40 years old) undergoing IVF treatment were recruited. Blood samples were collected at 3 different time points, the beginning of gonadotropin stimulation (the early follicular phase or T1), the scheduled day for ovum pick-up (OPU) (the late follicular phase or T2), and the day of OPU (T3). Meanwhile, biochemical and clinical parameters including the number of retrieved oocytes, matured oocytes, 2 pronuclear (2PN), and serum hCG were also determined. Moreover, fetus heart beat at 6 weeks of gestation was measured to classify the subjects into successful (n=10) and unsuccessful (n=20) clinical pregnancies. Serum AMH at T1 was significantly higher but serum FSH at T1 and T2 was significantly lower in the success group compared with the unsuccess group (P&lt;0.05 all). Serum kisspeptin at T2 (P=0.09) and serum estradiol at T3 (P=0.05) tended to be higher in the success group compared with non-success group. Serum kisspeptin at T1 had negative correlations with the number of retrieved oocytes (R=-0.511), matured oocytes (R=-0.388), and 2PN (R=-0.451) (P&lt;0.05 all). Serum kisspeptin at T2 had positive correlations with serum LH at T2 (R=0.455), serum kisspeptin at T3 (R=0.645), the number of retrieved oocytes (R=0.465), matured oocytes (R=0.432), and 2PN (R=0.445), and serum hCG levels (R=0.438) (P&lt;0.05 all). Serum kisspeptin at T3 had positive correlations with serum estradiol at T3 (R=0.380), the number of retrieved oocytes (R=0.601), matured oocytes (R=0.565), and 2PN (R=0.562) (P&lt;0.05 all). Follicular fluid kisspeptin levels had a negative correlation with serum FSH at T3 (R=-0.482) but a positive correlation with the number of matured oocytes (R=0.407) (P&lt;0.05 all). Kisspeptin levels in the follicular fluid (3.34 ± 3.74 ng/ml) were significantly higher than in serum at T3 (0.51 ± 0.13 ng/ml) (P&lt;0.01). As a result, kisspeptin at T2 was positively correlated with LH and clinical outcomes, suggesting that kisspeptin might play a role in augmentation of pre-ovulatory LH surge, improvement of oocyte maturation, and ovulation.
Thus, kisspeptin might be used as a potential predictor of successful IVF treatment. Reference: (1) Abbara A, et al. J Clin Endocrinol Metab. 2015;100(9):3322–31.